JP7781519B2 - グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 - Google Patents

グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法

Info

Publication number
JP7781519B2
JP7781519B2 JP2020511375A JP2020511375A JP7781519B2 JP 7781519 B2 JP7781519 B2 JP 7781519B2 JP 2020511375 A JP2020511375 A JP 2020511375A JP 2020511375 A JP2020511375 A JP 2020511375A JP 7781519 B2 JP7781519 B2 JP 7781519B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
gcgr
hyperammonemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020511375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531532A (ja
JP2020531532A5 (cg-RX-API-DMAC10.html
Inventor
はるか 岡本
シャイピン チェン
ジェスパー グロマダ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2020531532A publication Critical patent/JP2020531532A/ja
Publication of JP2020531532A5 publication Critical patent/JP2020531532A5/ja
Priority to JP2023169177A priority Critical patent/JP2023182691A/ja
Application granted granted Critical
Publication of JP7781519B2 publication Critical patent/JP7781519B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2020511375A 2017-08-22 2018-08-21 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 Active JP7781519B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023169177A JP2023182691A (ja) 2017-08-22 2023-09-29 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762548632P 2017-08-22 2017-08-22
US62/548,632 2017-08-22
PCT/US2018/047286 WO2019040471A1 (en) 2017-08-22 2018-08-21 METHODS OF TREATING UREA CYCLE DISORDERS BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023169177A Division JP2023182691A (ja) 2017-08-22 2023-09-29 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法

Publications (3)

Publication Number Publication Date
JP2020531532A JP2020531532A (ja) 2020-11-05
JP2020531532A5 JP2020531532A5 (cg-RX-API-DMAC10.html) 2021-09-30
JP7781519B2 true JP7781519B2 (ja) 2025-12-08

Family

ID=63638351

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020511375A Active JP7781519B2 (ja) 2017-08-22 2018-08-21 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法
JP2023169177A Pending JP2023182691A (ja) 2017-08-22 2023-09-29 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023169177A Pending JP2023182691A (ja) 2017-08-22 2023-09-29 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法

Country Status (6)

Country Link
US (2) US12139546B2 (cg-RX-API-DMAC10.html)
EP (1) EP3672620A1 (cg-RX-API-DMAC10.html)
JP (2) JP7781519B2 (cg-RX-API-DMAC10.html)
CA (1) CA3071387A1 (cg-RX-API-DMAC10.html)
MX (2) MX2020002057A (cg-RX-API-DMAC10.html)
WO (1) WO2019040471A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210642A1 (en) 2019-04-10 2020-10-15 Camp4 Therapeutics Corporation Methods and compositions for treating urea cycle disorders
EP4262781A4 (en) * 2020-12-16 2025-02-12 Rush University Medical Center Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders
WO2023122762A1 (en) * 2021-12-22 2023-06-29 Camp4 Therapeutics Corporation Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501512A (ja) 2010-11-23 2014-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体に対するヒト抗体
JP2014532179A (ja) 2011-09-30 2014-12-04 ハイペリオン セラピューティクス，インコーポレイテッド 窒素捕集薬の治療監視の方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5836308B2 (ja) 1977-02-10 1983-08-08 大塚製薬株式会社 抗体の製造方法
US4206199A (en) 1977-07-22 1980-06-03 Takeda Chemical Industries, Ltd. Novel glucagon fragment and its derivatives
JPS56163456A (en) 1980-05-21 1981-12-16 Otsuka Pharmaceut Co Ltd Preparation of antigen
US4423034A (en) 1980-10-16 1983-12-27 Toyo Jozo Kabushiki Kaisha Process for the preparation of antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3515112B2 (ja) 1992-08-28 2004-04-05 ノボ ノルディスク アクティーゼルスカブ グルカゴン・レセプタ
JP2729159B2 (ja) 1994-10-31 1998-03-18 日清製粉株式会社 ヒトグリセンチンのモノクローナル抗体、この抗体を産生するハイブリドーマおよびそれを用いるヒトグリセンチンの定量法
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7301036B2 (en) 2003-12-19 2007-11-27 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
SI1756064T1 (sl) 2004-06-04 2008-12-31 Merck & Co Inc Derivati pirazola, sestavki vsebujoäśi takĺ ne sestavine in postopki uporabe
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
DE602005017895D1 (de) 2004-07-07 2010-01-07 Merck & Co Inc Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
AU2005269792B9 (en) 2004-07-22 2008-11-27 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
US8084489B2 (en) 2005-02-11 2011-12-27 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
CN101146763A (zh) 2005-03-30 2008-03-19 默克公司 胰高血糖素受体拮抗剂化合物、含有这种化合物的组合物以及使用方法
AR056574A1 (es) 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
AU2007240315A1 (en) 2006-04-20 2007-11-01 Amgen Inc. GLP-1 compound/glucagon antibody compositions
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
MX2009008534A (es) 2007-02-09 2009-11-23 Metabasis Therapeutics Inc Antagonistas novedosos del receptor de glucagon.
AR070844A1 (es) 2008-03-27 2010-05-05 Lilly Co Eli Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2
US8623818B2 (en) 2008-05-16 2014-01-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonists, compositions, and methods for their use
US8436015B2 (en) 2008-09-15 2013-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010071750A1 (en) 2008-12-19 2010-06-24 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds
US20110281795A1 (en) 2009-01-28 2011-11-17 Songnian Lin Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010093535A1 (en) 2009-02-12 2010-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8809579B2 (en) 2009-02-13 2014-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2012188352A (ja) 2009-07-13 2012-10-04 Dainippon Sumitomo Pharma Co Ltd ３−（４−置換アルキル−フェニル）−２−フランカルボン酸誘導体およびその薬学的に許容される塩
FR2959129B1 (fr) * 2010-04-21 2013-02-01 Lucane Pharma Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations
JP2015505828A (ja) 2011-12-02 2015-02-26 イーライ リリー アンド カンパニー 抗グルカゴン抗体およびその使用
EP3194441A1 (en) 2014-09-16 2017-07-26 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501512A (ja) 2010-11-23 2014-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体に対するヒト抗体
JP2014532179A (ja) 2011-09-30 2014-12-04 ハイペリオン セラピューティクス，インコーポレイテッド 窒素捕集薬の治療監視の方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Gastroenterology, 1985年, 発行日, Vol.88, pp.750-756
Ｎｅｏｎａｔａｌ Ｃａｒｅ, 2012年, 発行日, 25(11), 1205-1210
Scandinavian Journal of Gastroenterology, 1990年, 発行日, Vol.25, Supplement 176, p.14

Also Published As

Publication number Publication date
CA3071387A1 (en) 2019-02-28
US20210130480A1 (en) 2021-05-06
JP2020531532A (ja) 2020-11-05
MX2020002057A (es) 2020-07-13
US12139546B2 (en) 2024-11-12
WO2019040471A1 (en) 2019-02-28
JP2023182691A (ja) 2023-12-26
WO2019040471A9 (en) 2019-03-21
EP3672620A1 (en) 2020-07-01
US20250101119A1 (en) 2025-03-27
MX2024011106A (es) 2024-09-18

Similar Documents

Publication Publication Date Title
CN103930444B (zh) 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
JP6375113B2 (ja) 被験者の特定のグループを処置する方法において使用するためのｐｃｓｋ９に対するヒト抗体
JP7633213B2 (ja) グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法
US10513557B2 (en) Anti-ASIC1 antibodies and uses thereof
US20140099312A1 (en) Methods for Treating Hypercholesterolemia and Reducing LDL-C Using Antibodies to PCSK9
CN109069868B (zh) 通过施用与angptl3抑制剂组合的pcsk9抑制剂治疗高脂血症患者的方法
US20250101119A1 (en) Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
JP2012511913A (ja) Ｐｃｓｋ９に対する高親和性ヒト抗体
KR20120104613A (ko) 사람 안지오포이에틴-유사 단백질 4에 대한 사람 항체
CN103314011A (zh) 胰高血糖素受体的人抗体
HK40114568A (en) Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
HK40006818A (en) Anti-asic1 antibodies and uses thereof
BR112014018651B1 (pt) Anticorpos anti-asic1, e composição farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200422

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230303

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230929

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231005

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251126

R150 Certificate of patent or registration of utility model

Ref document number: 7781519

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150